Daptomycin in the Treatment of Subjects With Infective Endocarditis or Bacteremia Due to S. Aureus [clinicaltrials:NCT00093067]

Bio2RDF identifier

NCT00093067

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT00093067

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT00093067

authority [clinicaltrials_vocabulary:authority]

clinicaltrials_resource:d942c8692d257084abf3ac87279faff6

brief summary [clinicaltrials_vocabulary:brief-summary]

The purpose of this stu ...... ylococcus aureus (S. aureus).

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

Daptomycin in the Treatment of ...... or Bacteremia Due to S. Aureus

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

To demonstrate that daptomycin is not inferior to comparator in the treatment of S. aureus bacteremia and IE as assessed by the Independent External Adjudication Committee (IEAC) Outcome at Test of Cure (TOC) in the Intention-to-Treat (ITT) population. [clinicaltrials_resource:00aec5ec6b431f1732e2eda91083c75d]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

To demonstrate that daptomycin is not inferior to comparator in the treatment of S. aureus bacteremia and IE as assessed by the Independent External Adjudication Committee (IEAC) Outcome at Test of Cure (TOC) in the Intention-to-Treat (ITT) population. [clinicaltrials_resource:22dd6517ef57bb54804bb8f79bcc8159]

To demonstrate that daptomycin is not inferior to comparator in the treatment of S. aureus bacteremia and IE as assessed by the Independent External Adjudication Committee (IEAC) Outcome at Test of Cure (TOC) in the Intention-to-Treat (ITT) population. [clinicaltrials_resource:5c7f1e7dd1f72ea5c242c625883f7499]

To demonstrate that daptomycin is not inferior to comparator in the treatment of S. aureus bacteremia and IE as assessed by the Independent External Adjudication Committee (IEAC) Outcome at Test of Cure (TOC) in the Intention-to-Treat (ITT) population. [clinicaltrials_resource:6961bd77952372de9706d6ae45f1479f]

To demonstrate that daptomycin is not inferior to comparator in the treatment of S. aureus bacteremia and IE as assessed by the Independent External Adjudication Committee (IEAC) Outcome at Test of Cure (TOC) in the Intention-to-Treat (ITT) population. [clinicaltrials_resource:87d4bf1de03bb18c089c058f6f16c0c0]

To demonstrate that daptomycin is not inferior to comparator in the treatment of S. aureus bacteremia and IE as assessed by the Independent External Adjudication Committee (IEAC) Outcome at Test of Cure (TOC) in the Intention-to-Treat (ITT) population. [clinicaltrials_resource:9511cb220db2494bb8489df46e03f6b3]

To demonstrate that daptomycin is not inferior to comparator in the treatment of S. aureus bacteremia and IE as assessed by the Independent External Adjudication Committee (IEAC) Outcome at Test of Cure (TOC) in the Intention-to-Treat (ITT) population. [clinicaltrials_resource:95957abbd7f98bdfbfc214316485c519]

To demonstrate that daptomycin is not inferior to comparator in the treatment of S. aureus bacteremia and IE as assessed by the Independent External Adjudication Committee (IEAC) Outcome at Test of Cure (TOC) in the Intention-to-Treat (ITT) population. [clinicaltrials_resource:abe154ca875521d1ddfe336f3c8d9595]

To demonstrate that daptomycin is not inferior to comparator in the treatment of S. aureus bacteremia and IE as assessed by the Independent External Adjudication Committee (IEAC) Outcome at Test of Cure (TOC) in the Intention-to-Treat (ITT) population. [clinicaltrials_resource:e7b83501adbb8a7fcef9d14c0caac989]

To demonstrate that daptomycin is not inferior to comparator in the treatment of S. aureus bacteremia and IE as assessed by the Independent External Adjudication Committee (IEAC) Outcome at Test of Cure (TOC) in the Intention-to-Treat (ITT) population. [clinicaltrials_resource:fb49c0a01810bee31ea66f58f6a5146e]

completion date [clinicaltrials_vocabulary:completion-date]

2005-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

detailed description [clinicaltrials_vocabulary:detailed-description]

Even with prompt treatm ...... ith adjunct gentamicin)

http://www.w3.org/2001/XMLSchema#string

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT00093067 [clinicaltrials_resource:4c97889e05b41a989f7bef16aa7b2b37]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2004-09-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

No

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

daptomycin [clinicaltrials_resource:6caa104ce919711ac8d6d216323578a7]

intervention browse [clinicaltrials_vocabulary:intervention-browse]

Daptomycin [clinicaltrials_resource:08f570289f495a84a773d5becef8579a]

keyword [clinicaltrials_vocabulary:keyword]

Cubist

http://www.w3.org/2001/XMLSchema#string

Gram-positive bacterial infections

http://www.w3.org/2001/XMLSchema#string

Staph Aureus

http://www.w3.org/2001/XMLSchema#string

bacteremia

http://www.w3.org/2001/XMLSchema#string

endocarditis

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2015-07-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

Cubist Pharmaceuticals Holdings LLC [clinicaltrials_resource:bc78980c4e815762d60838a5f547e067]

nct id [clinicaltrials_vocabulary:nct-id]

NCT00093067

http://www.w3.org/2001/XMLSchema#string

official title [clinicaltrials_vocabulary:official-title]

A Phase 3, Multicenter, Random ...... Bacteremia Due to Staph Aureus

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

DAP-IE-01-02

http://www.w3.org/2001/XMLSchema#string

overall status [clinicaltrials_vocabulary:overall-status]

Completed [clinicaltrials_resource:07ca5050e697392c9ed47e6453f1453f]

oversight [clinicaltrials_vocabulary:oversight]

United States: Food and Drug Administration [clinicaltrials_resource:77fa11db9aea1d8cd0ff35db5bc538f2]

phase [clinicaltrials_vocabulary:phase]

Phase 3 [clinicaltrials_resource:8357418e2694434468870b487644532d]

source [clinicaltrials_vocabulary:source]

Cubist Pharmaceuticals Holdings LLC [clinicaltrials_resource:bc78980c4e815762d60838a5f547e067]

start date [clinicaltrials_vocabulary:start-date]

2002-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT00093067 study design [clinicaltrials_resource:80fdae3dbe4c7808067ed67f680913f6]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT00093067

verification date [clinicaltrials_vocabulary:verification-date]

2006-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT00093067

http://www.w3.org/2001/XMLSchema#string

title

Daptomycin in the Treatment of ...... or Bacteremia Due to S. Aureus

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

label

Daptomycin in the Treatment of ...... s [clinicaltrials:NCT00093067]

@en